← Back to Search

Blood Purification

Seraph-100 + State of the Art Care for Septic Shock (PURIFY-RCT Trial)

N/A

Waitlist Available

Research Sponsored by Henry M. Jackson Foundation for the Advancement of Military Medicine

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up through study completion, an average of 90 days

Awards & highlights

PURIFY-RCT Trial Summary

This trial is to test a new extracorporeal blood purification (EBP) therapy to see if it is safe and effective in critically ill patients with pathogen associated shock.

Eligible Conditions

Septic Shock

PURIFY-RCT Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ through study completion, an average of 90 days

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~through study completion, an average of 90 days

This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 90 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Efficacy - ICU-free days in the first 28 days

Safety - Adverse Events

Secondary outcome measures

Hospital Stay

Kidney replacement therapy-free days in the first 28 days

Mortality

+3 more

PURIFY-RCT Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: 1- Seraph-100 plus State of the Art CareExperimental Treatment1 Intervention

The Seraph 100 Filter is a single use, disposable column packed with ultra-high molecular weight polyethylene beads which have been modified to contain endpoint attached heparin on the surface. Seraph 100 is an extracorporeal broad-spectrum sorbent hemoperfusion device for reduction of pathogens from the bloodstream. It is intended for use with standard, commercially available bloodlines compatible with the pump system used. Female Luer connectors are required to connect to the Seraph 100 blood ports.

Group II: 2 - State of the Art CareActive Control1 Intervention

"State of the Art care"is defined as the treatment algorithms outlined in the Surviving Sepsis Campaign for the treatment of septic shock, available at https://www.sccm.org/SurvivingSepsisCampaign/Home

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Henry M. Jackson Foundation for the Advancement of Military MedicineLead Sponsor

92 Previous Clinical Trials

92,874 Total Patients Enrolled

Uniformed Services University of the Health SciencesFED

116 Previous Clinical Trials

91,553 Total Patients Enrolled

ExThera Medical CorporationIndustry Sponsor

4 Previous Clinical Trials

389 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What objective is this medical trial attempting to attain?

"The primary goal of this trial is to evaluate the efficacy of ICU-free days in the first 28 days after hospital discharge. Secondary outcomes being tracked include mortality measured both at admission and post-treatment, ventilator free days within the same period, and kidney replacement therapy free days for a minimum 72 hour duration."

Answered by AI

Are there any openings for volunteers to participate in this research?

"As per clinicaltrials.gov, this medical trial is not currently accepting new participants. Initially posted on December 15th 2021 and last updated April 1st 2022, it does not appear to be recruiting at present; however there are 165 other studies open for enrolment right now."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Blood Purification for the Treatment of Pathogen Associated Shock

2021. "Blood Purification for the Treatment of Pathogen Associated Shock". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05011656.